tert-butyl (R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-((phenoxycarbonothioyl)oxy)ethyl)oxazolidine-3-carboxylate | 1016226-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-((phenoxycarbonothioyl)oxy)ethyl)oxazolidine-3-carboxylate
• CAS: 1016226-60-0
• 化学式: C₁₉H₂₄F₃NO₅S
• 分子量: 435.464
• InChiKey: VNFDZLHKWUDPFF-KWCCSABGSA-N

物化性质

• 沸点：
  436.7±55.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.67
• 重原子数：
  29.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  57.23
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-((phenoxycarbonothioyl)oxy)ethyl)oxazolidine-3-carboxylate 在 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 甲苯 为溶剂， 以84%的产率得到1,1-dimethylethyl (4S)-2,2-dimethyl-4-(2,2,2-trifluoroethyl)-1,3-oxazolidine-3-carboxylate
  参考文献：
  名称：

  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

  摘要：

  Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclinical species. Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib. Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.047
• 作为产物：
  描述：

  tert-butyl (R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-hydroxyethyl)oxazolidine-3-carboxylate 、 硫代氯甲酸苯酯 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 以96%的产率得到tert-butyl (R)-2,2-dimethyl-4-((S)-2,2,2-trifluoro-1-((phenoxycarbonothioyl)oxy)ethyl)oxazolidine-3-carboxylate
  参考文献：
  名称：

  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

  摘要：

  Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclinical species. Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib. Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.047